The latest news, research, and perspectives in myelofibrosis (MF). A primary subtype of myeloproliferative neoplasms (MPNs), this rare blood cancer scars the bone marrow so that it cannot properly produce blood cells.
Prithviraj Bose, MDMyelofibrosis | February 29, 2024
Myelofibrosis, a rare blood cancer, affects four to six per 100,000 individuals in the United States.
View More
Patrick DalyMyelofibrosis | February 29, 2024
An international working group collaborating with the EBMT and ELN updated the 2015 guidelines for HSCT in myelofibrosis.
Melissa BadamoMyelofibrosis | February 28, 2024
Ruxolitinib plus pelabresib was well tolerated and improved spleen and symptom burden in patients with myelofibrosis.
Keightley AmenMyelofibrosis | February 26, 2024
Parsaclisib plus ruxolitinib can improve symptoms and spleen volume in certain patients with myelofibrosis.
Blood Cancer TalksAcute Myeloid Leukemia | February 13, 2024
Dr. Patel and the hosts discuss the TRANSFORM-1 study, MANIFEST-2, AUGMENT-101, and more.
Claire Harrison, MD, FRCP, FRCPathMyelofibrosis | February 29, 2024
FREEDOM2 is a phase III study comparing fedratinib with best available therapy as a second-line treatment for myelofibrosis.
Michael Grunwald, MDMyeloproliferative Neoplasms | December 14, 2023
The REVEAL study identified five risk factors, including leukocytosis, duration of time with PV, and more.
Patrick DalyMyelofibrosis | March 1, 2024
The treatment led to reduced hepcidin levels when used alone or in combination with ruxolitinib.
Sangeetha Venugopal, MDMyelofibrosis | December 13, 2023
Venugopal highlights myelofibrosis research at ASH 2023.
Haifa Kathrin Al-Ali, MDMyelofibrosis | December 13, 2023
Dr. Al-Ali covers data on combined BET and JAK inhibition for patients with myelofibrosis presented at the 2023 ASH Meeting.
Melissa BadamoMyelofibrosis | December 11, 2023
SRSF2 and SF3B1 were the most common splicing mutations, followed by U2AF1 and ZRSR2.
Nico Gagelmann, MDMyelofibrosis | December 12, 2023
CALR and MPL mutations, which are associated with better outcomes, showed earlier mutation clearance than JAK2.
Emily HayesMyelofibrosis | December 13, 2023
Mass spectrometry–based proteomics were used to learn more about how MKs drive bone marrow fibrosis.
Emily HayesMyelofibrosis | December 13, 2023
Prevalence of symptoms was assessed with the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score.
Emily HayesMyelofibrosis | December 13, 2023
The retrospective study evaluated if pacritinib increased PLT counts in the phase III PERSIST-2 and phase II PAC203 studies.
Blood Cancers Today Staff WritersMyelofibrosis | December 13, 2023
Responses in hemoglobin, white blood cell, and platelet were 75%, 82%, and 74%, respectively, at 24 weeks.
Blood Cancers Today Staff WritersMyelofibrosis | December 13, 2023
Multivariable modeling showed a notable reduction in the risk of GVHD or relapse in the ATG group.
Blood Cancers Today Staff WritersMyelofibrosis | December 8, 2023
Hemoglobin and platelets are correlated with OS, while mutations in ASXL1, EZH2, IDH1/2, U2AF1, and SRSF2 are not.
Blood Cancers Today Staff WritersMyeloproliferative Neoplasms | December 7, 2023
Bomedemstat is an oral lysine-specific demethylase-1 (LSD1) inhibitor clinically active in patients with MPNs.
Patrick DalyMyelofibrosis | December 13, 2023
The study aimed to address “a substantial unmet need for therapies that alter disease trajectory" in patients with MF.
Editorial Board